Anthropic expands into biotech with drug discovery and lab partnerships

A new frontier in biotech

Anthropic is significantly broadening its reach beyond general AI by entering the biotechnology sector. The company is establishing a physical presence in the field by creating its own molecular biology laboratory. This move allows the firm to combine its computational power with hands-on scientific experimentation.

The expansion is supported by a series of strategic partnerships with six different organizations. These include major names like Bristol Myers Squibb and specialized firms such as Generate Biomedicines and BigHat Biosciences. These collaborations aim to put the Claude AI model to work across various stages of drug development.

The company's move into life sciences is also being fueled by acquisitions. Anthropic recently purchased Coefficient Bio, a startup focused on AI biotechnology. Additionally, they acquired Mithril Medicine, a firm whose founder utilized Claude to coordinate laboratory work on rare muscular dystrophy.

Accelerating drug discovery

One of the primary ways Anthropic is impacting the field is through the design of new therapies. For example, researchers at Generate Biomedicines used Claude Code to propose designs for CAR T-cell therapy. This specific treatment has traditionally been used for blood cell cancers, but researchers want to adapt it for solid tumors.

The AI-assisted designs resulted in a treatment component that was 70% shorter than the standard version. In laboratory tests, this shorter design was more effective at killing tumor cells and keeping immune cells active longer. It also allowed the cells to produce roughly 10 times as many receptors used to spot cancer.

Beyond discovery, the technology is being used to handle the administrative side of manufacturing. Enveda developed a language-model system to review completed pharmaceutical batch records. This system focuses on production documentation, which is a separate task from determining if a drug actually works.

From data to the lab

Anthropic's approach relies on a feedback loop between digital analysis and physical science. In September, the company reported that Claude identified an unusual enzyme system linked to repeating DNA sequences. While the system had features similar to CRISPR, its exact function was unknown at the time of discovery.

Following this AI identification, human scientists performed laboratory experiments to investigate the finding further. This highlights the current balance of the industry, where AI identifies patterns and humans conduct the validation. The company noted that this specific finding did not yet establish a new gene-editing treatment.

The company's internal life sciences research group was formed in the spring of 2026. This group serves as the foundation for the company's deeper integration into biology. It allows Anthropic to move from simply providing a tool to actively participating in the scientific process.

Industry adoption and scale

The commercial interest in Anthropic's technology is already substantial within the pharmaceutical industry. According to the company's October 26 initial public offering filing, nine of the world's 10 largest pharmaceutical companies were customers as of September 30. While the specific names were not disclosed, the scale of adoption is significant.

The filing also detailed the company's plans for continued investment in life sciences expertise. This includes both forming new partnerships and making further acquisitions to bolster its capabilities. The goal is to integrate AI into the core operations of the world's leading medicine producers.

This rapid adoption suggests that the industry views AI as a necessary component for modern R&D. By automating data analysis and improving diagnostics, these companies hope to speed up the overall decision-making process in medicine. This transition marks a shift toward a more data-centric model for pharmaceutical development.

The role of human oversight

Despite the capabilities of AI, experts emphasize that human involvement remains a non-negotiable requirement in medicine. Dr. Michael Riddle, a physician and inventor at Mesogen, notes that AI is making it easier to analyze large datasets and improve diagnostics. However, he argues that regenerative medicine still requires strong human oversight and validation from doctors.

The technology is currently viewed as a tool to speed up research and support personalized treatments rather than a replacement for medical professionals. It excels at processing biological data faster than humans can, but the final decisions regarding patient care remain human-centric. This balance is essential for maintaining safety in complex medical environments.

As Anthropic continues to develop potential medicines, the timeline for human impact remains a key focus. For instance, Mithril Medicine reported promising mouse results for muscular dystrophy treatments. If development remains successful, the company indicated that human trials could begin as early as late 2028.